Effect of chronic hepatitis C virus infection on bone mineral density in pediatric renal transplant recipients

الملخص EN

Previous studies have suggested that loss of bone mineral density (BMD) frequently occurs in patients with chronic viral liver disease, presenting with histologically proven liver cirrhosis.

However, little is known about the occurrence of bone disease in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection.

Furthermore, to the best of our knowledge, such an effect has never been studied in pediatric renal transplant recipients.

The aim of this study was to assess the impact of HCV infection on BMD in pediatric renal transplant patients.

We performed a crosssectional study to assess BMD and HCV in 83 patients who received living renal allotransplants in the Mansoura Urology and Nephrology Center between 1983 and 2005.

The mean age of the study patients at transplantation was 13.4 ± 2.9 years; there were 53 males (63.9%) and 30 females (36.1%).

BMD was studied using dual energy X-ray absorptiometry at various time intervals up to 16 years after transplantation (mean duration after transplantation was 48 ± 34 months, range 12– 192 months).

Thirty-three patients tested positive for HCV-RNA (positive group) and 50 patients were negative (negative group), and we compared the BMD between the two groups.

Before transplantation, 58 patients (69.9%) were on maintenance hemodialysis, four (4.8%) were on peritoneal dialysis and 21 (25.3%) were pre-emptive.

Among the HCV-positive group, six patients (18.2%) had osteoporosis, 17 (51.5%) had osteopenia and ten (30.3%) had normal BMD.

In the HCV-negative group, ten patients (20.0%) had osteoporosis, 24 (48.0%) had osteopenia and 16 (32.0%) had normal BMD.

The difference was not significant between the two groups (P = 0.9).

Also, there was no significant difference in the serum creatinine, calcium, phosphorus and parathormone levels between the two groups.

Our results suggest that chronic HCV infection does not pose a risk for low BMD in pediatric renal transplant recipients.